DISHMAN CARBOGEN AMCIS LIMITED

CARBOGEN AMCIS Shanghai Facility Receives First Drug Manufacturing License from China's NMPA

- CARBOGEN AMCIS Shanghai facility has been awarded its first Drug Manufacturing License by China's National Medical Products Administration following comprehensive GMP compliance inspection. - The 40,000 m² facility in Shanghai Chemical Industry Park offers full-service capabilities from early R&D to commercial production with four segregated units and reactor capacities up to 6,300 litres. - The license approval marks a strategic milestone in CARBOGEN AMCIS' Asian expansion and strengthens the company's ability to serve pharmaceutical partners throughout the region. - The facility employs over 140 staff and is equipped to handle highly potent compounds up to category 3 with comprehensive analytical and GMP release services.